Nicholas Piramal Enters into a Joint Venture with ARKRAY Inc Japan
The 49:51 joint venture aims at marketing diagnostic products, mainly self-monitoring blood glucose system in the Indian market.
BD Acquires Right to Negotiate Business Relationship for Accelr8’s BACcel® Technology
Becton Dickinson has purchased an exclusive right to negotiate for a business relationship to develop Accelr8’s BACcel® rapid diagnostic platform.
Cancer Cell Line Developed that is Resistant to new Cancer Therapy
Researchers found the HDAC inhibitor-resistant cell line resistant to many therapies but highly sensitive to heat shock protein 90 inhibitors, another emerging cancer treatment.
ImmunoVaccine Technologies to Acquire Immunotope
The acquisition will bring together IVT's signature VacciMax® platform with Immunotope's portfolio of immunotherapeutic antigens and antigen discovery platform.
Beckman Coulter Collaborates in Multisite Research Project for Cardiovascular Disease Markers
The collaborative research will seek to discover genetic signatures for cardiovascular disease and obesity-related hypertension.
AVEO Pharmaceuticals and Lilly Sign Collaboration for Clinical Drug Response Project
Agreement highlights growing interest in novel biology platform that identifies clinical response of cancer drugs.
Buck Institute and Neurobiological Technologies Partner to Develop Treatment for Huntington's Disease
The research involves fibroblast growth factor-2 (FGF-2), a naturally occurring protein that has been studied extensively for its neuroprotective properties.
IPSOGEN to Undertake Pilot Study on JAK2 Cancer Biomarker with Astrazeneca
The pilot agreement with AstraZeneca to evaluate molecular services and products in cancer research.
Vermillion Announces Issuance of U.S. Patent Covering Method for Aiding Diagnosis of Kidney Disorder
The U.S. Patent office has issued Vermillion U.S. Patent No. 7,297,556 for aiding diagnosis of nephrotic syndrome.
ImmunoCellular Therapeutics Agrees to Acquire Molecular Antibody Technology
ImmunoCellular has entered into an agreement with Molecular Discoveries covering the IMUC’s acquisition of all monoclonal antibody related technology owned by MDC.